Soluble Aβ homeostasis in AD and DS

Impairment of anti-amyloidogenic protection by lipoproteins

Etsuro Matsubara, Yoshiki Sekijima, Takahiko Tokuda, Katsuya Urakami, Masakuni Amari, Masami Shizuka-Ikeda, Yasushi Tomidokoro, Masaki Ikeda, Takeshi Kawarabayashi, Yasuo Harigaya, Shu Ichi Ikeda, Tetsuro Murakami, Koji Abe, Eiichi Otomo, Shunsaku Hirai, Blas Frangione, Jorge Ghiso, Mikio Shoji

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

In order to assess whether lipoproteins are physiologically able to balance and modulate the sAβ homeostasis in vivo, soluble Aβ levels in lipoprotein-depleted plasma were measured as a function of age in normal controls, Alzheimer's disease (AD) patients, and Down's syndrome (DS) cases. The reshaping of sAβ homeostasis, in particular the sAβ42-lipoprotein interaction, takes place over normal-60's, whereas mild AD patients appear to have impaired this anti-amyloidogenic mechanism resulting in a significant increase of lipoprotein-free sAβ42. Similar loss of function takes place in Down's syndrome patients. Lipoprotein-free sAβ remains significantly elevated from the pre-symptomatic through the symptomatic stages of the disease, and declines with the progression of the AD-like pathology. The dissociation of sAβ from lipoprotein-particles also occurs in brain parenchyma and the presence of soluble dimeric lipoprotein-free Aβ prior to its parenchymal deposition in AD brains would support the hypothesis that functionally declined lipoproteins may be major determinants in the production of metabolic conditions leading to higher levels of sAβ species and cerebral amyloidosis.

Original languageEnglish
Pages (from-to)833-841
Number of pages9
JournalNeurobiology of Aging
Volume25
Issue number7
DOIs
Publication statusPublished - Aug 2004

Fingerprint

Down Syndrome
Lipoproteins
Alzheimer Disease
Homeostasis
Brain
Pathology

Keywords

  • Aβ dimer
  • Alzheimer's disease
  • Down's syndrome
  • Lipoprotein-free Aβ
  • sAβ homeostasis

ASJC Scopus subject areas

  • Clinical Neurology
  • Biological Psychiatry
  • Developmental Neuroscience
  • Neurology
  • Psychology(all)

Cite this

Matsubara, E., Sekijima, Y., Tokuda, T., Urakami, K., Amari, M., Shizuka-Ikeda, M., ... Shoji, M. (2004). Soluble Aβ homeostasis in AD and DS: Impairment of anti-amyloidogenic protection by lipoproteins. Neurobiology of Aging, 25(7), 833-841. https://doi.org/10.1016/j.neurobiolaging.2003.10.004

Soluble Aβ homeostasis in AD and DS : Impairment of anti-amyloidogenic protection by lipoproteins. / Matsubara, Etsuro; Sekijima, Yoshiki; Tokuda, Takahiko; Urakami, Katsuya; Amari, Masakuni; Shizuka-Ikeda, Masami; Tomidokoro, Yasushi; Ikeda, Masaki; Kawarabayashi, Takeshi; Harigaya, Yasuo; Ikeda, Shu Ichi; Murakami, Tetsuro; Abe, Koji; Otomo, Eiichi; Hirai, Shunsaku; Frangione, Blas; Ghiso, Jorge; Shoji, Mikio.

In: Neurobiology of Aging, Vol. 25, No. 7, 08.2004, p. 833-841.

Research output: Contribution to journalArticle

Matsubara, E, Sekijima, Y, Tokuda, T, Urakami, K, Amari, M, Shizuka-Ikeda, M, Tomidokoro, Y, Ikeda, M, Kawarabayashi, T, Harigaya, Y, Ikeda, SI, Murakami, T, Abe, K, Otomo, E, Hirai, S, Frangione, B, Ghiso, J & Shoji, M 2004, 'Soluble Aβ homeostasis in AD and DS: Impairment of anti-amyloidogenic protection by lipoproteins', Neurobiology of Aging, vol. 25, no. 7, pp. 833-841. https://doi.org/10.1016/j.neurobiolaging.2003.10.004
Matsubara, Etsuro ; Sekijima, Yoshiki ; Tokuda, Takahiko ; Urakami, Katsuya ; Amari, Masakuni ; Shizuka-Ikeda, Masami ; Tomidokoro, Yasushi ; Ikeda, Masaki ; Kawarabayashi, Takeshi ; Harigaya, Yasuo ; Ikeda, Shu Ichi ; Murakami, Tetsuro ; Abe, Koji ; Otomo, Eiichi ; Hirai, Shunsaku ; Frangione, Blas ; Ghiso, Jorge ; Shoji, Mikio. / Soluble Aβ homeostasis in AD and DS : Impairment of anti-amyloidogenic protection by lipoproteins. In: Neurobiology of Aging. 2004 ; Vol. 25, No. 7. pp. 833-841.
@article{3109eadaa47b4b3baeba31ee0fd1a4ef,
title = "Soluble Aβ homeostasis in AD and DS: Impairment of anti-amyloidogenic protection by lipoproteins",
abstract = "In order to assess whether lipoproteins are physiologically able to balance and modulate the sAβ homeostasis in vivo, soluble Aβ levels in lipoprotein-depleted plasma were measured as a function of age in normal controls, Alzheimer's disease (AD) patients, and Down's syndrome (DS) cases. The reshaping of sAβ homeostasis, in particular the sAβ42-lipoprotein interaction, takes place over normal-60's, whereas mild AD patients appear to have impaired this anti-amyloidogenic mechanism resulting in a significant increase of lipoprotein-free sAβ42. Similar loss of function takes place in Down's syndrome patients. Lipoprotein-free sAβ remains significantly elevated from the pre-symptomatic through the symptomatic stages of the disease, and declines with the progression of the AD-like pathology. The dissociation of sAβ from lipoprotein-particles also occurs in brain parenchyma and the presence of soluble dimeric lipoprotein-free Aβ prior to its parenchymal deposition in AD brains would support the hypothesis that functionally declined lipoproteins may be major determinants in the production of metabolic conditions leading to higher levels of sAβ species and cerebral amyloidosis.",
keywords = "Aβ dimer, Alzheimer's disease, Down's syndrome, Lipoprotein-free Aβ, sAβ homeostasis",
author = "Etsuro Matsubara and Yoshiki Sekijima and Takahiko Tokuda and Katsuya Urakami and Masakuni Amari and Masami Shizuka-Ikeda and Yasushi Tomidokoro and Masaki Ikeda and Takeshi Kawarabayashi and Yasuo Harigaya and Ikeda, {Shu Ichi} and Tetsuro Murakami and Koji Abe and Eiichi Otomo and Shunsaku Hirai and Blas Frangione and Jorge Ghiso and Mikio Shoji",
year = "2004",
month = "8",
doi = "10.1016/j.neurobiolaging.2003.10.004",
language = "English",
volume = "25",
pages = "833--841",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Soluble Aβ homeostasis in AD and DS

T2 - Impairment of anti-amyloidogenic protection by lipoproteins

AU - Matsubara, Etsuro

AU - Sekijima, Yoshiki

AU - Tokuda, Takahiko

AU - Urakami, Katsuya

AU - Amari, Masakuni

AU - Shizuka-Ikeda, Masami

AU - Tomidokoro, Yasushi

AU - Ikeda, Masaki

AU - Kawarabayashi, Takeshi

AU - Harigaya, Yasuo

AU - Ikeda, Shu Ichi

AU - Murakami, Tetsuro

AU - Abe, Koji

AU - Otomo, Eiichi

AU - Hirai, Shunsaku

AU - Frangione, Blas

AU - Ghiso, Jorge

AU - Shoji, Mikio

PY - 2004/8

Y1 - 2004/8

N2 - In order to assess whether lipoproteins are physiologically able to balance and modulate the sAβ homeostasis in vivo, soluble Aβ levels in lipoprotein-depleted plasma were measured as a function of age in normal controls, Alzheimer's disease (AD) patients, and Down's syndrome (DS) cases. The reshaping of sAβ homeostasis, in particular the sAβ42-lipoprotein interaction, takes place over normal-60's, whereas mild AD patients appear to have impaired this anti-amyloidogenic mechanism resulting in a significant increase of lipoprotein-free sAβ42. Similar loss of function takes place in Down's syndrome patients. Lipoprotein-free sAβ remains significantly elevated from the pre-symptomatic through the symptomatic stages of the disease, and declines with the progression of the AD-like pathology. The dissociation of sAβ from lipoprotein-particles also occurs in brain parenchyma and the presence of soluble dimeric lipoprotein-free Aβ prior to its parenchymal deposition in AD brains would support the hypothesis that functionally declined lipoproteins may be major determinants in the production of metabolic conditions leading to higher levels of sAβ species and cerebral amyloidosis.

AB - In order to assess whether lipoproteins are physiologically able to balance and modulate the sAβ homeostasis in vivo, soluble Aβ levels in lipoprotein-depleted plasma were measured as a function of age in normal controls, Alzheimer's disease (AD) patients, and Down's syndrome (DS) cases. The reshaping of sAβ homeostasis, in particular the sAβ42-lipoprotein interaction, takes place over normal-60's, whereas mild AD patients appear to have impaired this anti-amyloidogenic mechanism resulting in a significant increase of lipoprotein-free sAβ42. Similar loss of function takes place in Down's syndrome patients. Lipoprotein-free sAβ remains significantly elevated from the pre-symptomatic through the symptomatic stages of the disease, and declines with the progression of the AD-like pathology. The dissociation of sAβ from lipoprotein-particles also occurs in brain parenchyma and the presence of soluble dimeric lipoprotein-free Aβ prior to its parenchymal deposition in AD brains would support the hypothesis that functionally declined lipoproteins may be major determinants in the production of metabolic conditions leading to higher levels of sAβ species and cerebral amyloidosis.

KW - Aβ dimer

KW - Alzheimer's disease

KW - Down's syndrome

KW - Lipoprotein-free Aβ

KW - sAβ homeostasis

UR - http://www.scopus.com/inward/record.url?scp=4544307730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544307730&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2003.10.004

DO - 10.1016/j.neurobiolaging.2003.10.004

M3 - Article

VL - 25

SP - 833

EP - 841

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

IS - 7

ER -